We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+57.27%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.67B
AUM Growth
+$471M
Cap. Flow
-$59.6M
Cap. Flow %
-3.58%
Top 10 Hldgs %
75.81%
Holding
42
New
5
Increased
4
Reduced
20
Closed
1

Top Buys

Rank Stock Value
1
RVNC
Revance Therapeutics, Inc.
RVNC
+$21.5M
2
GOSS icon
Gossamer Bio
GOSS
+$2.57M
3
ZGNX
Zogenix, Inc.
ZGNX
+$2.06M
4
ATNX
Athenex, Inc. Common Stock
ATNX
+$1.96M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$1.71M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$21M
2
STAA icon
STAAR Surgical
STAA
+$18.7M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.7M
4
UTHR icon
United Therapeutics
UTHR
+$12.4M
5
WMGI
Wright Medical Group Inc
WMGI
+$6.96M

Sector Composition

Rank Sector Weight
1 Healthcare 83.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$2.81M 0.17%
104,100
+74,600
+253% +$2.06M
GOSS icon
27
Gossamer Bio
GOSS
$86.8M
$2.65M 0.16%
+204,214
New +$2.57M
ATNX
28
DELISTED
Athenex, Inc. Common Stock
ATNX
$2.55M 0.15%
+9,260
New +$1.96M
SNDX icon
29
Syndax Pharmaceuticals
SNDX
$1.77B
$1.89M 0.11%
127,700
+61,600
+93% +$938K
APRE icon
30
Aprea Therapeutics
APRE
$8.46M
$1.83M 0.11%
+2,362
New +$1.55M
DNTH icon
31
Dianthus Therapeutics
DNTH
$6.29B
$1.46M 0.09%
+12,163
New +$1.71M
ALIM
32
DELISTED
Alimera Sciences
ALIM
$1.27M 0.08%
200,919
– –
KZR
33
DELISTED
Kezar Life Sciences
KZR
$1.06M 0.06%
+20,509
New +$1.03M
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$960K 0.06%
37,400
– –
TVTX icon
35
Travere Therapeutics
TVTX
$5.86B
$959K 0.06%
47,000
– –
URGN icon
36
UroGen Pharma
URGN
$2.39B
$640K 0.04%
24,500
– –
MRNS
37
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$318K 0.02%
31,330
– –
ALDX icon
38
Aldeyra Therapeutics
ALDX
$91.7M
$306K 0.02%
73,500
– –
VIRX
39
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$306K 0.02%
33,214
– –
ACGN
40
DELISTED
Aceragen Inc
ACGN
$138K 0.01%
4,537
– –
NERV icon
41
Minerva Neurosciences
NERV
$187M
$131K 0.01%
4,540
– –
WMGI
42
DELISTED
Wright Medical Group Inc
WMGI
– –
-242,940
Closed -$6.96M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q2 2020 Portfolio in Review

As of Q2 2020, Palo Alto Investors held 42 positions worth $1.67B, up 39% from $1.19B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Palo Alto Investors withdrew a net $59.6M in Q2 2020, closing 1 position and reducing 20 holdings. Its most notable exit was Wright Medical Group Inc, an estimated $6.96M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 88% a quarter earlier.

Against the trend, Palo Alto Investors opened a new position in Gossamer Bio worth $2.65M.

  • Palo Alto Investors's largest Q2 2020 buy was Gossamer Bio: 204,214 shares worth $2.65M.
  • Palo Alto Investors added most to Revance Therapeutics, Inc. in Q2 2020, an estimated $21.5M increase.
  • Palo Alto Investors's biggest Q2 2020 reduction was Alexion Pharmaceuticals, cutting an estimated $21M.
  • Palo Alto Investors fully exited Wright Medical Group Inc in Q2 2020, selling an estimated $6.96M.
  • Palo Alto Investors's ten largest holdings make up 76% of its $1.67B portfolio in Q2 2020.
  • Palo Alto Investors opened 5 new positions and closed 1 in Q2 2020.
  • Palo Alto Investors's portfolio value rose 39% quarter-over-quarter to $1.67B.

Based on Palo Alto Investors's 13F filing for Q2 2020, filed 14 Aug 2020.